GW-501516, also known as Cardarine, was first created in the mid-1990s by pharmaceutical companies Glaxo Smith Kline and Ligand Pharmaceuticals to help treat metabolic and cardiovascular diseases. Drug development was abandoned in 2007, and GW501516 use started to become popular among athletes, fitness enthusiasts, and bodybuilders. Performance enhancement from Cardarine was of main interest. A summary of Cardarine benefits include increased endurance, increased fat utilization, improved HDL (high density lipoprotein) levels, and decrease LDL (low density lipoprotein levels).
MK677, also known as Ibutamoren or
Nutrobal, is an orally active, non-peptide human growth hormone secretagogue
with a 24 hour half life. MK677 has a mechanism of action by functioning as a selective
agonist of the ghrelin receptor. MK677 is frequently falsely categorized as a SARM
(selective androgen receptor modulator). This false categorization is largely a
result of the fitness, athlete, and bodybuilding communities and their interest
in MK677 results such as fat loss, muscle growth, anti-aging benefits, improved
mood, improved sleep, and more purported benefits. MK677 advantages include
being an alternative to using injectable human growth hormone (HGH), or
injectable GHRP and GHRH peptides. MK677 cost also offers a significant savings
compared to the aforementioned peptides.
LGD4033 is a Selective Androgen Receptor Modulator (SARM) that is also known by the names Ligandrol and Anabolicum. LGD4033 (Ligandrol/Anabolicum) is known for its ability to promote an increase in lean muscle mass which doesn’t accompany the side effects associated with steroidal SARMs or anabolic-androgenic steroids (AAS). This is a property that makes LGD4033 (Ligandrol/Anabolicum) of strong interest within the medical and pharmaceutical industries, as well as with athletes, bodybuilders and individuals interested in performance enhancement.
Selective Androgen Receptor Modulators (SARMs) have been a topic of interest within the biotechnology, pharmaceutical, medical, (and of course, performance enhancement) communities since the mid-90s when they were first presented in the field of science. However, during the 1940s, an initial class of SARMs (steroidal SARMs) were investigated by way of modification of the hormone testosterone. They have been utilized for therapeutic applications in treating numerous ailments including hypogonadism, cancer, osteoporosis, and different infections that influence muscle and bone wasting. These steroidal SARMs had a substantial impact on the growth of muscle tissue because of their strong binding affinity for the androgen receptors on skeletal muscle. However, due to this generation of SARMs being steroidal, they had other effects systemically – many of which were in the form of undesirable side effects, such as gynecomastia, endocrine disruption, sexual side effects, cardiovascular complications, prostate enlargement, as well as liver and kidney damage.